Overview

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.

Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, our proprietary anti-interleukin-33 antibody, for the treatment of atopic dermatitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps.

In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).

Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.

Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.

Strategy

Advancing our lead wholly-owned programs for the treatment of severe inflammatory disease

We are advancing etokimab, our proprietary anti-interleukin-33 antibody, for the treatment of atopic dermatitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps. In addition, we intend to develop our anti-IL-36R antibody (ANB019) for the treatment of generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).

Identifying emerging target biology opportunities in inflammation

We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation by understanding and translating biological breakthroughs into first-in-class therapeutic antibodies. Our approach includes assessment of human genetics and tissue pathology to understand the relevance of emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to create new product candidates and position our current and future programs for rapid clinical proof-of-concept achievement.

Expanding our proprietary pipeline by generating new antibody product candidates using our technology platform

Using our proprietary antibody generation platform, we are able to rapidly develop novel therapeutic antibodies against emerging targets. Our goal is to advance multiple additional wholly-owned new therapeutic antibody program to IND submission.

Retaining rights to strategic products in key commercial markets

We intend to retain ownership and control of our pipeline programs to key inflection points. We may build sales and marketing capabilities in selected specialty markets that we believe can be served with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing resources to advance through development and commercialization.

Management

Hamza Suria

Hamza Suria

President and CEO

Hamza Suria was appointed CEO in 2011 and has since led AnaptysBio’s transformation from its early platform technology focus to the development of a robust antibody product pipeline across key therapeutic areas.

+
Marco Londei, M.D.

Marco Londei, M.D.

Chief Medical Officer

Marco Londei, M.D., joined AnaptysBio from Bristol-Myers Squibb (BMS) where he was Therapeutic Area Head, Immunosciences and responsible for early clinical and translational research for a portfolio of immune-related therapeutics.

+
Eric Loumeau

Eric Loumeau

Interim Chief Financial Officer and General Counsel

Eric Loumeau joined AnaptysBio in August 2018 with more than twenty years of experience in biotech.

+
Hemant Kumar, Ph.D.

Hemant Kumar, Ph.D.

Senior Vice President, Manufacturing

Hemant Kumar joined AnaptysBio in November 2017 with more than 20 years of experience in biologicals manufacturing.

+
Beth Mueller

Beth Mueller

Senior Vice President, Human Resources

Beth Mueller joined AnaptysBio in October 2019 with over 20 years of experience in all aspects of human resources, including organizational development, talent acquisition, and compensation in the biotechnology industry.

+
Margaret (Peggy) Marino, Ph.D.

Margaret (Peggy) Marino, Ph.D.

Vice President, Project Management

Margaret Marino, Ph.D., joined AnaptysBio from Pfizer, where she was responsible for external R&D innovation and project management across a number of biologics programs within the CovX Biotech Unit.

+
Nancy Sacco, Ph.D.

Nancy Sacco, Ph.D.

Vice President, Clinical Development

Nancy Sacco joined AnaptysBio in August 2018 with 20+ years of pharmaceutical experience through all phases of Clinical Development and product registration.

+
Lewis Gryziewicz, Pharm.D.

Lewis Gryziewicz, Pharm.D.

Vice President, Regulatory Affairs

Lewis Gryziewicz, PharmD joined AnaptysBio in January 2019 with more than 30 years of experience in Regulatory Affairs and Research and Development. 

+
Marilyn Kehry, Ph.D.

Marilyn Kehry, Ph.D.

Vice President, Cell Biology & Functional Biology

Marilyn Kehry joined AnaptysBio in April 2011 with more than 25 years of experience in drug discovery research and project leadership in the biotechnology and pharmaceutical industry.

+
Stephen Parmley, Ph.D.

Stephen Parmley, Ph.D.

Vice President, Molecular Biology & Protein Sciences

Stephen Parmley joined AnaptysBio in November of 2015 with more than 30 years of experience in protein engineering, immunology and project leadership.

+
Peter Smith

Peter Smith

Vice President, Commercial Strategy

Peter Smith joined AnaptysBio in November 2018 with more than 30 years of experience in sales, marketing and program leadership in biopharma.

+
David McKeon

David McKeon

Vice President, Controller

David McKeon joined AnaptysBio in April 2017 with more than 20 years of accounting and finance experience. Prior to joining AnaptysBio, Mr. McKeon served as Chief Financial Officer for Mad Catz Interactive, Inc., a designer and manufacturer of video game peripherals.

+

Board Of Directors

James N. Topper, M.D., Ph.D.

Chairman of AnaptysBio
Managing General Partner at Frazier Healthcare

Jamie Topper, M.D., Ph.D., is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in the same year. Throughout his 11 years as a General Partner, Dr. Topper has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies.

+

Hollings Renton

Former President and CEO of Onyx Pharmaceuticals

Hollings Renton has previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals from 1993 to 2008 and as the Chairman of the Board from 2000 to 2008.

+

John Schmid

Former CFO of Auspex Pharmaceuticals

John Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 until its sale to Teva Pharmaceuticals, Inc. in June 2015. Prior to Auspex, he co-founded Trius Therapeutics, Inc., where he served as Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc. in September 2013.

+

Dennis Fenton, Ph.D.

Former Executive Vice President, Amgen

Dr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President.

+

J. Anthony Ware, M.D.

Former SVP Product Development, Lilly Bio-Medicines, Eli Lilly and Company

Dr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas.

+

Laura J. Hamill

Former Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences

Laura J. Hamill joined our Board of Directors in September 2019. Ms. Hamill has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions.

+

Hamza Suria

President and CEO, AnaptysBio, Inc.

Hamza Suria was appointed CEO in 2011 and has since led AnaptysBio’s transformation from its early platform technology focus to the development of a robust antibody product pipeline across key therapeutic areas.

+

Research and Development Committee

Michael Gallatin, Ph.D.

Former Vice President and Scientific Director of ICOS Corporation

Michael Gallatin, Ph.D., is a former Vice President and Scientific Director of ICOS Corporation, where his responsibilities included discovery, preclinical research, medicinal chemistry and process chemistry groups, including those responsible for worldwide development and launch of Tadalafil (Cialis®).

+

Jan de Vries, Ph.D.

Former Head of the Novartis Research Institutes for BioMedical Research

Jan de Vries, Ph.D., is the former Head of the Novartis Research Institutes for BioMedical Research in Basel, Switzerland. Prior to that, he was Head of the Novartis Research Institute in Vienna and Global Head of the Disease Area Autoimmunity, Transplantation and Inflammation.

+

James N. Topper, M.D., Ph.D.

Chairman of AnaptysBio
Managing General Partner at Frazier Healthcare

Jamie Topper, M.D., Ph.D., is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in the same year. Throughout his 11 years as a General Partner, Dr. Topper has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies.

+

J. Anthony Ware, M.D.

Former SVP Product Development, Lilly Bio-Medicines, Eli Lilly and Company

Dr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas.

+

Dennis Fenton, Ph.D.

Former Executive Vice President, Amgen

Dr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President.

+

Contact

AnaptysBio, Inc.

10421 Pacific Center Court
Suite 200
San Diego, CA 92121

 

Phone: (858) 362-6295
Fax: (858) 362-6296
info@anaptysbio.com

General Information

info@anaptysbio.com

Job Opportunities

Please see our Job Openings page.